|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBXN11 |
Gene summary for UBXN11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBXN11 | Gene ID | 91544 |
| Gene name | UBX domain protein 11 | |
| Gene Alias | COA-1 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q5T124 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91544 | UBXN11 | LZE7T | Human | Esophagus | ESCC | 4.07e-03 | 2.18e-01 | 0.0667 |
| 91544 | UBXN11 | LZE24T | Human | Esophagus | ESCC | 1.30e-08 | 5.62e-01 | 0.0596 |
| 91544 | UBXN11 | LZE21T | Human | Esophagus | ESCC | 4.53e-03 | 3.35e-01 | 0.0655 |
| 91544 | UBXN11 | LZE6T | Human | Esophagus | ESCC | 1.12e-09 | 2.50e-01 | 0.0845 |
| 91544 | UBXN11 | P1T-E | Human | Esophagus | ESCC | 1.68e-03 | 3.17e-01 | 0.0875 |
| 91544 | UBXN11 | P2T-E | Human | Esophagus | ESCC | 7.55e-33 | 6.25e-01 | 0.1177 |
| 91544 | UBXN11 | P4T-E | Human | Esophagus | ESCC | 1.16e-09 | 1.12e-01 | 0.1323 |
| 91544 | UBXN11 | P5T-E | Human | Esophagus | ESCC | 4.01e-13 | 2.03e-01 | 0.1327 |
| 91544 | UBXN11 | P8T-E | Human | Esophagus | ESCC | 1.62e-16 | 2.28e-01 | 0.0889 |
| 91544 | UBXN11 | P10T-E | Human | Esophagus | ESCC | 3.43e-09 | 2.04e-01 | 0.116 |
| 91544 | UBXN11 | P11T-E | Human | Esophagus | ESCC | 2.13e-04 | 2.35e-01 | 0.1426 |
| 91544 | UBXN11 | P12T-E | Human | Esophagus | ESCC | 2.54e-10 | 1.27e-01 | 0.1122 |
| 91544 | UBXN11 | P15T-E | Human | Esophagus | ESCC | 1.86e-07 | 1.49e-01 | 0.1149 |
| 91544 | UBXN11 | P16T-E | Human | Esophagus | ESCC | 6.73e-14 | 2.48e-01 | 0.1153 |
| 91544 | UBXN11 | P17T-E | Human | Esophagus | ESCC | 1.79e-05 | 3.13e-01 | 0.1278 |
| 91544 | UBXN11 | P19T-E | Human | Esophagus | ESCC | 2.52e-04 | 3.14e-01 | 0.1662 |
| 91544 | UBXN11 | P20T-E | Human | Esophagus | ESCC | 3.11e-14 | 3.38e-01 | 0.1124 |
| 91544 | UBXN11 | P21T-E | Human | Esophagus | ESCC | 3.48e-12 | 2.68e-01 | 0.1617 |
| 91544 | UBXN11 | P22T-E | Human | Esophagus | ESCC | 1.00e-06 | 1.71e-01 | 0.1236 |
| 91544 | UBXN11 | P23T-E | Human | Esophagus | ESCC | 2.37e-14 | 2.86e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
| GO:004316112 | Liver | Cirrhotic | proteasome-mediated ubiquitin-dependent protein catabolic process | 184/4634 | 412/18723 | 4.52e-19 | 8.85e-17 | 184 |
| GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
| GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
| GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
| GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
| GO:0010498110 | Oral cavity | LP | proteasomal protein catabolic process | 224/4623 | 490/18723 | 9.57e-25 | 4.00e-22 | 224 |
| GO:0043161110 | Oral cavity | LP | proteasome-mediated ubiquitin-dependent protein catabolic process | 190/4623 | 412/18723 | 1.08e-21 | 2.93e-19 | 190 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBXN11 | SNV | Missense_Mutation | novel | c.516N>A | p.His172Gln | p.H172Q | Q5T124 | protein_coding | tolerated(0.17) | benign(0.019) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| UBXN11 | SNV | Missense_Mutation | novel | c.1097N>G | p.Ala366Gly | p.A366G | Q5T124 | protein_coding | tolerated(0.17) | benign(0.419) | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| UBXN11 | SNV | Missense_Mutation | c.691N>A | p.Glu231Lys | p.E231K | Q5T124 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| UBXN11 | SNV | Missense_Mutation | c.1424N>T | p.Pro475Leu | p.P475L | Q5T124 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| UBXN11 | insertion | Frame_Shift_Ins | novel | c.1097_1098insGT | p.Arg367SerfsTer47 | p.R367Sfs*47 | Q5T124 | protein_coding | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| UBXN11 | SNV | Missense_Mutation | novel | c.1208C>G | p.Ser403Cys | p.S403C | Q5T124 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| UBXN11 | SNV | Missense_Mutation | rs566971320 | c.676N>T | p.Arg226Trp | p.R226W | Q5T124 | protein_coding | deleterious(0.01) | possibly_damaging(0.642) | TCGA-VS-A8EG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| UBXN11 | SNV | Missense_Mutation | rs371990639 | c.1100N>A | p.Arg367Gln | p.R367Q | Q5T124 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| UBXN11 | SNV | Missense_Mutation | rs200278768 | c.893T>C | p.Leu298Pro | p.L298P | Q5T124 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBXN11 | SNV | Missense_Mutation | novel | c.1132T>G | p.Leu378Val | p.L378V | Q5T124 | protein_coding | deleterious(0) | benign(0.241) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |